In 2016, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency approved the first ctDNA-based test to prescribe EGFR inhibitors in patients with non-small cell lung cancer (NSCLC) - Cobas EGFR mutation test v2 (Kwapisz, 2017; U.S Food and Drug Administration, 2022; U.S Food and Drug Administration, 2023). Here, EGFR is linked to non-small cell lung carcinoma.